Arlington Capital Partners has acquired Micron Technologies, a provider of particle size engineering and related analytical services to the pharmaceutical industry, in partnership with the company’s management team.
“Micron is an ideal platform investment in a compelling growth industry and we look forward to working closely with the company’s management team to expand the business aggressively, both organically and through acquisition,” said David Wodlinger, a Principal at Arlington Capital.
Micron Technologies provides advanced solubility enhancement services including particle size reduction and analytical services for pharmaceutical companies worldwide. Services provided include jet milling, mechanical milling, containment processing and associated analytical services including material characterization testing and stability monitoring. The company operates a new state-of-the-art 84,000 square foot CGMP facility in Malvern, PA and a 19,000 square foot CGMP facility in Dartford, UK. (Current Good Manufacturing Practices (CGMP) are followed by pharmaceutical and biotech firms to ensure that the products meet specific requirements for identity, strength, quality, and purity). Micron Technologies has approximately 100 employees and is headquartered in Malvern, PA (www.microntech.com).
“Micron’s ability to provide leading bio-availability solutions across the drug development spectrum, from clinical phases to the commercial market, positions the company as a trusted long-term partner with its pharmaceutical clients for their most demanding drug development needs” said Matt Altman, a Partner at Arlington Capital Partners. “We are enthusiastic about building upon the company’s leadership position and eager to continue to support the company as it enhances and expands its global particle size engineering and analytical service offerings.”
Arlington Capital Partners has $1.5 billion of committed capital and focuses on buyouts and recapitalizations of companies valued from $50 million to $500 million. Sectors of interest include healthcare services, aerospace & defense, government contracting, business services and software. The firm is based in Washington, DC (www.arlingtoncap.com).
“We are extremely excited about our partnership with Arlington Capital. Arlington has a successful history of investing in healthcare and pharmaceutical services and shares our vision for growing Micron’s global capabilities and service offerings,” said Joseph Drost, CEO of Micron. “Arlington’s ability to provide significant strategic and capital support will further enable Micron to continue to expand our leading global position and better serve our worldwide pharmaceutical client base.”
Fairmount Partners advised Micron Technologies on the transaction. Fairmount Partners specializes in assisting companies with mergers and acquisitions, capital raising and strategic advice. Fairmount completes most of its transactions in its key focus areas: Technology & Software, IT & Business Services, Healthcare, and Consumer & Industrial, and has completed transactions throughout North and South America, Europe and Asia. The firm is based in the Philadelphia suburb of West Conshohocken (www.fairmountpartners.com).
© 2013 PEPD • Private Equity’s Leading News Magazine • 3-21-13
